Companies

Companies

    Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.

    Scientists working

    Coming soon: Joblistings!

    Learn more about
    their stories

    Venkat Reddy, Greg Timblin, Ingrid Caton & David Moffat

    Tenant Spotlight on Inapill: A Novel Approach to Interrupting Inflammation

    “We hope this new oral therapeutic targeting proinflammatory immunometabolism will have ‘pipeline-in-a-pill’ potential,” says CEO and co-founder Greg Timblin. “Once it garners FDA approval in one inflammatory indication, it could be used in the clinic as a treatment across multiple inflammatory diseases. Perhaps it could even provide benefit to patients with more complex diseases where excessive inflammation is thought to be a driving factor, such as cardiometabolic and neurodegenerative diseases.” Read post
    Shakked Halperin

    Rewrite and Replace: Shakked Halperin, Serial Entrepreneur

    “CRISPR offered a pair of DNA scissors that were going to change the world,” Shakked says. “But I didn’t want to just cut. I wanted to rewrite with full control over the target sequence, so with Rewrite I turned to nature’s DNA writer – DNA polymerases – and made something closer to a pencil.” Read post
    Beth Zotter and Julian Rees

    Umaro and HOPO, Bakar Labs Tenants, Partner in DOE-Funded Project to Extract Rare Earth Elements from Seaweed

    Two Bakar Labs tenants, Umaro and HOPO, have forged an unlikely partnership to extract rare earth elements from seaweed in a project funded by a $1.78 million grant from the US Department of Energy. The award was announced Thursday, November 2, through the ARPA-E program. The joint project will explore seaweed as a sustainable source of rare earth elements, such as neodymium and dysprosium, crucial for advanced manufacturing. Sectors that could benefit include renewable electricity, computer chips, and electric vehicles. Read post
    The Minutia team, all business. Bottom row from left: Molly Klimak, Sean Meyer, Victor Mann, Katy Digovich, Janna Register, Sapna Puri, Debapriya Saha. Top from left: Helen Clark, Bill Hyun, Christian Schuetz, Johnny Ma, Jessica Chavez.

    Hope on the Horizon: How Minutia Plans to Cure Diabetes with Cell Therapy

    “I grew up in Silicon Valley, around this energy that a company is a great vehicle to build something of value,” said Katy. “I want to build things that need to exist in the world, and at Minutia, we’re doing this in two ways: cell therapy and the cell based sensors that can help ensure safety and improve efficacy of cell therapies.” Minutia’s cell therapy is a functional cure for type 1 diabetes that involves transplanting insulin producing cells just underneath the skin. Not only is this safer and less invasive compared to some existing cell therapies, which require surgically implanting cells into the liver, but Minutia’s cells are paired with nanosensors that bring the medical marvels of science fiction to real life. Read post
    Yana Aznavour and Max Sorokin

    Empowering Women, One Test at a Time: The Endometrics Approach to Endometriosis

    Roughly 190 million women suffer from endometriosis worldwide. In endometriosis, the tissue similar to the lining of the uterus grows outside the uterus, causing debilitating pelvic pain and infertility. The chronic pain can last for almost a lifetime – but despite the severity of the pain, many women don’t even realize they have a disease. And it can be difficult for doctors to tell, too. As the CEO and founder of Bakar Labs tenant Endometrics, Dr. Aznavour is dedicated to bridging the gap between patients and easy, painless diagnosis. Read post
    Sampling Human co-founders Daniel Georgiev, Martin Cienciala, and Hynek Kasl (L-R) at Ocean Beach shortly after their arrival in San Francisco from the Czech Republic.

    Tenant Spotlight on Sampling Human: Using Biology to Analyze Biology

    Anyone who’s had a blood draw as a patient – in short, everyone – knows that what the doctor gets to work with is a basic count of red and white blood cells. But there’s so much information that we’re missing, which could help inform and develop much more precise treatment. Daniel Georgiev and Sampling Human want to solve this problem. Their solution: using biology to analyze biology. Read post
    The Regel Therapeutics leadership team

    Tenant Spotlight on Regel Therapeutics: A New Approach to Gene Therapy

    “I always used to enjoy science and technological innovation. For a scientist, curiosity leads to discovery, but it is a need that leads to invention. In the back of my mind, I always knew that to make a clinical product into a reality, I have to take the technology out of the lab and develop it in an industry setting. Patients and their caregivers motivated me to take this leap into entrepreneurship,” says Navneet Matharu. Read post
    Scientist
    Want to learn more?

    Become a tenant at Bakar Labs

    Get in touch